| January | February | March | April | May | June | July | August | September | October | November | December |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Asys Hitech GmbH (Austria) | Harvard Bioscience Inc. (HBIO) | 12/7 | 12/7 | ND | Harvard Bioscience acquired Asys, which should add about $1.5M to $2M in revenue for the company in 2002 |
| Atlantic Stem Cells Inc. | Anthrogenesis Corp. | 12/6 | 12/6 | ND | Anthrogenesis acquired Atlantic Stem Cells for an undisclosed amount |
| Biosonix Ltd. (Israel) | Neoprobe Corp. (OTC BB:NEOP) | 9/7 | 12/11 | $3.4 | Neoprobe completed an acquisition of Biosonix issuing about 9.7M shares of stock for all of Biosonix's outstanding shares |
| Cartesian Technologies Inc. | Genomic Solutions Inc. (GNSL) | 9/7 | 12/20 | $16 | Genomic Solutions issued 6.8M shares of common stock and spent $2.5M in cash to acquire Cartesian |
| Corporate Technology Development Inc. | Endorex Corp. (AMEX:DOR) | 8/1 | 12/3 | $7.7 | Endorex issued about 9.4M shares to acquire CTD, a value of $7.7M based on the Dec. 2 stock price |
| Group Lafon (France) | Cephalon Inc. (CEPH) | 12/3 | 12/3 | $450 | Cephalon bought the French pharmaceutical company for $450M in cash |
| Lifecodes Corp. | Orchid Biosciences Inc. (ORCH) | 10/1 | 12/6 | $12.7 | Orchid acquired Lifecodes for $12.7M in a stock-for-stock transaction under which Lifecodes shareholders received about 6.6M shares |
| The Intergen Co. | Serologicals Corp. (SERO) | 11/6 | 12/14 | $45 | Serologicals acquired The Intergen Co. for $45M in cash, less the amount necessary to complete the expansion of Intergen's Toronto manufacturing facility |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Astralis LLC | Hercules Development Group (OTC BB:HDVG) | 9/28 | 11/14 | ND | Astralis and Hercules closed their definitive merger agreement with Hercules issuing about 28M shares of stock |
| Axys Pharmaceuticals Inc. (AXPH) | Celera Genomics Group (NYSE:CRA) | 6/13 | 11/16 | $173.4 | Celera acquired Axys by issuing Celera stock equivalent to $4.65 per Axys share; the value of the deal is based on Axys' 37.3M shares outstanding |
| Hesed Biomed Inc. | Abgenix Inc. (ABGX) | 11/14 | 11/14 | $15.9 | Abgenix acquired Hesed by issuing about 540,000 shares of common stock valued at about $25 each and paying about $360,000 in cash in exchange for all of Hesed's shares; Abgenix also assumed about $2M in Hesed's debt |
| NZ Corp. | Lipid Sciences Inc. | 11/30 | 11/30 | ND | The companies merged; the merged company will be called Lipid Sciences Inc. and will trade on Nasdaq under the symbol LIPD |
| Vaxis Therapeutics Corp. (Canada) | Cellegy Pharmaceuticals Inc. (CLGY) | 11/29 | 11/29 | $4 | Cellegy acquired Vaxis for less than $4M payable primarily in Cellegy stock plus potential earnout payments over a seven-year period |
| Vysis Inc. (VYSI) | Abbott Laboratories Inc. | 10/24 | 11/30 | $355 | Abbott acquired Vysis for a cash tender offer of 10.1M shares of Vysis common stock |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| BioNative AB (Sweden) | Viragen Inc. (AMEX:VRA) and Viragen (Europe) Ltd. (OTC BB:VERP) | 7/12 | 10/1 | $2.5 | Viragen's subsidiary, Viragen Europe, acquired BioNative for 2.9M shares, valued at about $2.5M; BioNative will be called ViraNative |
| CCEL Bio-Therapies (subsidiary of Cryo-Cell International Inc.; CCEL) | Saneron Therapeutics Inc. | 10/12 | 10/12 | ND | CCEL and Saneron merged; Cryo-Cell will own about 43% of the merged company |
| ESC Merger Sub Inc. (subsidiary of Ergo Science Corp.) | Ergo Science Corp. (OTC BB:ERGG before Nov. 5; OTC BB:ERGO after Nov. 5) | 10/19 | 10/19 | ND | Ergo Science merged with its wholly-owned subsidiary; the merged company will be called Ergo Science Corp. |
| Lifecodes Corp. | Orchid BioSciences Inc. (ORCH) | 10/2 | 10/2 | $12.7 | Orchid acquired Lifecodes by issuing about 6.5M shares in return for all of Lifecodes' outstanding shares; the deal was valued at about $12.7M |
| The Althexis Company Inc. | Microcide Pharmaceuticals Inc. (MCDE) | 7/30 | 10/25 | $22.22 | Microcide acquired The Althexis Company in a stock swap worth about $22M; Microcide issued about 5.3M shares of stock for all outstanding shares of Althexis; the new company is called Essential Therapeutics Inc. (ETRX) |
| Viral Genetics Inc. | 5 Starliving Online Inc. (OTC BB:HTHV) | 9/19 | 10/3 | $44 | 5 Starliving acquired Viral for 29.7M shares, valuing the deal at about $44M |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Astralis LLC | Hercules Development Corp. | 9/28 | 9/28 | $110.6 | Hercules acquired Astralis with 28M shares of new stock; the deal is worth $110.6M |
| Calydon Inc. | Cell Genesys Inc. (CEGE) | 8/1 | 9/5 | $17.4 | Cell Genesys acquired Calydon in a stock-for-stock transaction involving 935,000 shares of Cell Genesys stock valued at $17.4M; the deal also includes the assumption of up to about $2.6M in Calydon liabilities |
| Cell Map (unit of GlaxoSmithKline plc; UK) | Cellzome GmbH (Germany) | 9/27 | 9/27 | ND | Cellzome acquired Cell Map; GSK will become a minority shareholder in Cellzome; other terms were not disclosed |
| Gemini Genomics plc (UK; GMNI) | Sequenom Inc. (SQNM) | 5/29 | 9/20 | $238 | Companies completed their merger in a stock-for-stock exchange valued at $238M; Sequenom issued about 12.9M shares, and assumed all outstanding options and warrants to purchase an aggregate of 1.5M shares of Sequenom |
| Novazyme Pharmaceuticals Inc. | Genzyme Corp. (GENZ) | 8/7 | 9/27 | $137.5 | Genzyme acquired Novazyme for $137.5M in stock; stockholders also are eligible to receive two additional stock payments totaling $87.5M, based on U.S. marketing approval of two Novazyme products |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Arcaris Inc. | Deltagen Inc. (DGEN) | 7/26 | 8/15 | $12.5 | Deltagen bought Arcaris by issuing 765,000 new shares of stock and by paying $450,000 in cash plus transaction fees and expenses; it also will reserve about 50,000 shares for Arcaris employee options, and will issue an additional 550,000 shares of common stock upon the achievement of certain milestones |
| Hemoxymed Inc. | Ophidian Pharmaceuticals Inc. (OTC BB:OPHD) | 4/17 | 8/23 | ND | Ophidian acquired all of Hemoxymed's outstanding stock in exchange for its issuance of 19M new, unregistered shares |
| Isolagen Technologies Inc. | American Financial Holding Inc. (OTC BB:ANFC) | 8/22 | 8/22 | ND | American Financial acquired Isolagen in a stock-for-stock transaction; American Financial raised more than $2M in an equity private placement of common stock and converted $1.45M principal amount of Isolagen debt and about $625,000 of accrued liabilities to equity |
| MultiCell Associates Inc. | Exten Industries Inc. (OTC BB:EXTI) | 4/2 | 8/1 | ND | Exten completed the acquisition of MultiCell, through a cash and stock transaction |
| Proligo LLC | Degussa Corp. (subsidiary of Degussa AG; Germany) | 8/29 | 8/31 | US$14.3 | Degussa acquired Proligo for US$14.3M paid to Gilead Sciences Inc. for its 49% ownership; it also paid $18M to Proligo for expansion purposes |
| Richcor Resources Ltd. (Canada) | BioxelPharma Inc. (Canada) | 8/2 | 8/1 | ND | BioxelPharma merged with Richcor, granting 1,322 common shares of Richcor for each common share of Bioxel |
| V.I. Technologies Inc.'s plasma operations (VITX) | Ampersand Ventures and other investors | 8/14 | 8/14 | $32 | Investors acquired the plasma operations; V.I. Technologies will receive $25M in cash, and the rest over the next two years; the new company will be called Precision Pharma Services Inc. |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Aronex Pharmaceuticals Inc. (ARNX) | Antigenics Inc. (AGEN) | 4/24 | 7/12 | $28.6 | Antigenics acquired Aronex for 0.0594 shares of Antigenics' stock for each Aronex share |
| Aurora Biosciences Corp. (ABSC) | Vertex Pharmaceuticals Inc. (VRTX) | 4/30 | 7/18 | $592 | Vertex acquired Aurora in a $592M stock-for-stock transaction |
| Avicenna Medica Inc. (Canada) | KS Biomedix Holdings plc (UK; LSE:KSB) | 6/27 | 7/17 | 46.44 (US$65.4) | KS Biomedix acquired Avicenna for 41.9M in shares and 4.54M in cash |
| Biotechna U.A.B. (Lithuania) | Sicor Inc. (SCRI) | 7/25 | 7/25 | ND | Sicor purchased Biotechna by issuing 1.5M shares of common stock and a warrant to purchase up to 150,000 shares of common stock at an exercise price of $3.50 per share; Sicor will assume about $30M in debt |
| Cambridge Discovery Chemistry Inc. (unit of Millennium Pharmaceuticals Inc.; MLNM) | Signature BioScience Inc. | 7/16 | 7/16 | ND | Signature acquired Cambridge from Millennium for an undisclosed amount |
| Coelacanth Corp. | Lexicon Genetics Inc. (LEXG) | 6/14 | 7/12 | $32 | Lexicon completed its merger with Coelacanth, issuing about 2.9M shares of Lexicon common stock |
| Cerebrotec | ViaCell Inc. | 7/25 | 7/25 | ND | ViaCell acquired Cerebrotec, and will form the ViaCell Neuroscience Division |
| Computer-aided molecular design unit of Protherics plc (UK) | Tularik Inc. (TLRK) | 7/12 | 7/12 | ND | Tularik acquired the Protherics unit for an undisclosed amount |
| DanProcess A/S (subsidiary of Pantax; Denmark) | Amersham Pharmacia Biotech (unit of Nycomed Amersham plc; NYSE:NYE) | 7/23 | 7/23 | ND | Amersham said it acquired 100% of DanProcess for an undisclosed amount |
| Focal Inc. (FOCL) | Genzyme Corp. (GENZ) | 4/26 | 7/2 | $15.9 | Genzyme completed its acquisition of Focal and incorporated its operations into Genzyme Biosurgery; about 2.1M shares of Genzyme Biosurgery stock were issued in the transaction |
| Gendaq Ltd. (UK) | Sangamo BioSciences Inc. (SGMO) | 6/28 | 7/6 | $40 | Sangamo issued about 2.1M shares of common stock to acquire all of Gendaq's outstanding shares, and it will reserve an additional 125,352 shares to assume all of Gendaq's outstanding options |
| Genetic Models Inc. | Charles River Laboratories International Inc. (NYSE:CRL) | 7/3 | 7/20 | $4 | Charles River acquired Genetic Models for $4M in cash |
| International Market Supply Ltd. (UK) | Harvard Bioscience Inc. (HBIO) | 7/3 | 7/3 | $1.4 | Harvard Bioscience acquired all of the outstanding stock of International Market Supply for $1.4M |
| Momentum Healthcare Ltd. (UK) | Cellomics Inc. | 7/12 | 7/12 | ND | Cellomics acquired Momentum Healthcare for an undisclosed amount |
| Periodontix Inc. | Demegen Inc. (OTC BB:DBOT) | 2/9 | 7/16 | ND | Demegen completed its acquisition of the majority of the assets of Periodontix for an undisclosed amount |
| Rosetta Inpharmatics Inc. (RSTA) | Merck Co. Inc. | 5/11 | 7/19 | $540 | Merck acquired Rosetta |
| Shearwater Corp. | Inhale Therapeutic Systems Inc. (INHL) | 5/22 | 7/2 | $164 | Inhale acquired Shearwater for $72.5M in cash and 4M shares of newly issued Inhale stock, valuing the transaction at $164M |
| Unipex (France) | Atrium Biotechnologies Inc. (subsidiary of AEterna Laboratories Inc.; Canada; AELA; TSE:AEL) | 7/3 | 7/3 | $20 | Atrium acquired Unipex for about $20M |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Apollo BioPharmaceuticals Inc. | MitoKor | 5/9 | 6/27 | ND | MitoKor acquired Apollo for a combination of stock and cash |
| NeuroGeneration Corp. and NeuroGenomics Corp. | Theratechnologies Inc. (Canada; TSE:TH) | 6/21 | 6/21 | C$18 (US$11.83) | Theratechnologies acquired the two California companies for a total consideration of C$18M in shares of its new subsidiary, Celmed BioSciences |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Annovis Inc. | Transgenomic Inc. (TBIO) | 5/1 | 5/29 | $19.4 | Transgenomic acquired Annovis for 1.9M Transgenomic shares and $500,000 in cash |
| BioChem Pharma Inc. (Canada; BCHM) | Shire Pharmaceuticals Group plc (UK; SHPGY) | 12/11 | 5/11 | $4B | The companies merged in a deal involving 231.2M new ordinary shares and worth $4B |
| Cambridge Drug Discovery Ltd. | BioFocus plc | 5/23 | 5/30 | 27.5 (US$39) | BioFocus purchased Cambridge Drug Discovery for US$39M |
| Eligix Inc. | BioTransplant Inc. (BTRN) | 12/11 | 5/16 | $55 | BioTransplant issued 6.6M shares of its common stock to Eligix shareholders, acquiring Eligix for about $55M |
| HemaSure Inc. (OTC BB:HMSR) | Whatman Bioscience Inc. (subsidiary of Whatman plc; UK; LSE:WHM) | 5/30 | 5/30 | $10 | HemaSure completed the sale of its assets, except for cash, cash equivalents and marketable securities; consists of a $10M payment and a reimbursement amount that covers net change in cash from the ongoing business operations from Nov. 1, 2000, through the closing date; HemaSure also will get 4 percent royalties up to $12M in sales of filtration products using its technology |
| Intellivax International Inc. (Canada) | ID Biomedical Corp. (Canada; TSE:IDP) | 3/27 | 5/16 | C$20 (US$12.75) | ID Biomedical issued 4M shares to Intellivax shareholders, acquiring the company in a deal worth $12.75M |
| NuMax Pharmaceuticals Inc. | Biota Holdings Ltd. (Australia; ASX:BTA) | 5/21 | 5/21 | $8 | Biota acquired NuMax and will spend $8M over two years to fund NuMax's drug discovery programs; it also will issue employee stock; NuMax will become Biota Inc., the U.S.-based division |
| Sawady Group (Japan) | Qiagen NV (the Netherlands; QGENF) | 5/1 | 5/1 | US$18 | Qiagen acquired Sawady through the issuance of 854,987 shares of common stock in exchange for all of the outstanding capital stock of Sawady Technology Co. Ltd. and Omgen Co Ltd.; it also gained a majority position in Accord Co. Ltd. |
| Union Biometrica Inc. | Harvard Bioscience Inc. (HBIO) | 5/31 | 5/31 | $75 | Harvard Bioscience will issue 659,282 unregistered shares of its stock, 263,202 options to purchase stock and $7.5M in cash for all outstanding Union shares and options |
| Warner Instruments Corp. | Harvard Bioscience Inc. (HBIO) | 5/1 | 5/1 | ND | Harvard Bioscience acquired Warner Instruments |
| Xenometrix Inc. (OTC BB:XENO) | Discovery Partners International Inc. (DPII) | 2/28 | 5/9 | $1.7 | Discovery Partners completed its acquisition of Xenometrix for 59 cents per share; with 2.9M shares outstanding, the deal is valued at $1.7M |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Advanced Biotechnologies Ltd. (UK) | Apogent Technologies Inc. (NYSE:AOT) | 4/10 | 4/10 | ND | Apogent acquired Advanced Biotechnologies, which logged sales revenues for 2000 of about $21M |
| Armstrong Pharmaceuticals (division of Celltech Manufacturing Inc.) | Andrx Corp. (ADRX) | 2/12 | 4/2 | $18 | Andrx acquired Armstrong for $18M in cash |
| Lisfarma Importacao, Exportacao e Comercio Ltda. (Brazil) | Genzyme General (division of Genzyme Corp.) | 4/2 | 4/2 | $1.1 | Genzyme acquired Lisfarma for about $1.1M |
| Ophidian Pharmaceuticals Inc. (OTC BB:OPHD) | Promega Corp. | 9/1 | 4/17 | $1.2 | Ophidian sold its assets to Promega; shareholders will receive $961,000 in proceeds; the company will retain the rest to cover liabilities and expenses |
| ProBio Inc. (Australia) | Pharming Group NV (the Netherlands; EASDAQ:PHAR) | 11/28 | 4/3 | US$4 | Acquisition is worth at least $4M in milestone payments over the next two years; in addition, Pharming will transfer shares to the former ProBio shareholders at the share price of EUR12.52 (US$11.17) |
| Soltec Research Pty. Ltd. (division of F.H. Faulding & Co. Ltd.; Australia) | Connetics Corp. (CNCT) | 3/21 | 4/23 | $16.2 | Connetics acquired Soltec for about US$16.2M in cash |
| Xenova Group plc (XNVA) | Cantab Pharmaceuticals plc (CNTBY) | 2/20 | 4/9 | 124 (US$179) | The companies merged in an all-share deal; Cantab investors received 11 new Xenova shares for every seven Cantab shares |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Canberra Industries (unit of Packard Bioscience Co.; PBSC) | Cogema (France) | 11/30 | 3/1 | $170 | Packard completed the sale of Canberra to Cogema for $170M |
| Display Systems Biotech A/S (Denmark) | NeuroSearch A/S (Denmark) | 2/21 | 2/21 | DKK29 (US$3.4) | NeuroSearch acquired Display Systems for US$3.4M and will call the new company Azign Bioscience A/S |
| Myelos Corp. | Bio-Technology General Corp. (BTGC) | 2/22 | 3/20 | $35 | Bio-Technology acquired Myelos for $35; a future payment of $30M in cash and stock is contingent upon the filing of a new drug application for Prosaptide |
| NuCycle Therapy Inc. | Integrated Health Technologies Inc. (IHTC) | 3/5 | 3/5 | ND | Integrated Health acquired NuCycle Therapy for an undisclosed amount |
| PanVera Corp. | Aurora Biosciences Corp. (ABSC) | 11/17 | 3/1 | $86 | Aurora completed its merger with PanVera, agreeing to issue up to 1.9M shares |
| Sensus Drug Development Corp. | Pharmacia Corp. (NYSE:PHA) | ND | 3/7 | ND | Pharmacia acquired the rest of Sensus as part of a 1999 agreement in which it first acquired 20% of the company |
| Trega Biosciences Inc. (TRGA) | LION bioscience AG (Germany; LEON) | 12/27 | 3/15 | $12.25 | LION issued about 500,000 American depositary shares, making the acquisition worth $12.25M |
| Virco Group NV (Belgium) | Tibotec Group NV (Belgium) | 1/19 | 3/15 | ND | The companies completed their merger; the combined group will be called Tibotec-Virco NV |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Bunsen Rush Laboratories Inc. | Arena Pharmaceuticals Inc. (ARNA) | 12/27 | 2/20 | $15 | Arena acquired Bunsen Rush for $15M in an all-cash transaction |
| Camitro Corp. | ArQule Inc. (ARQL) | 1/16 | 2/1 | $95 | ArQule acquired Camitro for 3.4M shares or about $95M |
| Cellmark Diagnostics (subsidiary of AstraZeneca plc) | Orchid BioSciences Inc. (ORCH) | 2/13 | 2/13 | ND | Purchase price was not disclosed, but the deal included an equity stake in Orchid for AstraZeneca |
| Genetic Solutions Pty. Ltd. (Australia) | GenomicFX LP | 2/2 | 2/2 | ND | GenomicFX acquired the livestock genomics company Genetic Solutions for an undisclosed amount |
| Primedica Corp. (unit of Genzyme Transgenics Corp.; GZTC) | Charles River Laboratories International Inc. (NYSE:CRL) | 2/7 | 2/27 | $52 | Charles River acquired Primedica for $52M - a $26M cash payment, $16.5M in restricted Charles River stock and the assumption of $9.5M in debt |
| Symphar SA (Switzerland) | Ilex Oncology Inc. (ILXO) | 2/14 | 2/14 | $30 | Ilex bought out Symphar for $30M in equal amounts of cash and stock |
| Company Acquired | Acquired By Or Merged With | Date Announced | Date Completed | Value (M) | Terms/Details |
| Auxien Corp. | Mycotech Corp. | 1/8 | 1/8 | ND | The two companies merged to form Emerald BioAgricuture Corp. focused on the development, manufacture and marketing of natural crop-protection and yield enhancement products |
| Bradford Particle Design plc (UK) | Inhale Therapeutic Systems Inc. (INHL) | 12/21 | 1/9 | $200 | Inhale acquired Bradford for $200M; the offer is $180M in newly issued Inhale stock and $20M in cash; the offer involves about 3.7M shares |
| Chesapeake Biological Laboratories (Canada; CBLI) | Cangene Corp. (Canada; TSE:CNJ) | 10/30 | 1/4 | $31.3 | Cangene said its tender offer to purchase all of the outstanding shares of Chesapeake expired 1/3; it has tendered more than 6.8M shares, 93% of the company; shareholders who did not tender their shares received $4.60 per share, net to the stockholder in cash |
| GeneFormatics Inc. | Structure Function Genomics LLC | 1/16 | 1/16 | ND | The companies merged; no further details were disclosed |
| IGT Pharma Inc. (Canada) | Neurotrophic BioScience Inc. (Canada) | 10/00 | 1/8 | US$9 | IGT issued 10.734M shares to acquire all the outstanding shares of Neurotrophic in a merger of equals; the companies became Prescient NeuroPharma Inc. (CDNX:PRE) |
| MAII Holdings Inc. (MAII; formerly Medical Alliance Inc.) | ICN Pharmaceuticals Inc. (NYSE:ICN) | 1/3 | 1/3 | $14.4 | ICN acquired MAII for $14.4M in cash |
| Molecular Biosystems Inc. (OTC BB:MBIO) | Alliance Pharmaceutical Corp. (ALLP) | 10/00 | 1/3 | $6.16 | Alliance completed its acquisition of Molecular Biosystems for 770,000 shares |
| NeuroVir Therapeutics Inc. | MediGene AG (Germany; Neuer Markt:MDG) | 11/00 | 1/17 | $77 | MediGene acquired NeuroVir in an all-stock deal |
| New Chemical Entities Inc. | Albany Molecular Research Inc. (AMRI) | 12/19 | 1/25 | $22.4 | Albany Molecular acquired New Chemical for $22.4M and assumed $600,000 in outstanding debt |
| Oy Quattrogene Ltd. (Finland) | Eurogene Ltd. (UK) | 1/26 | 1/26 | ND | Eurogene acquired Oy in an all-stock transaction; the combined company will be known as Ark Therapeutics Ltd. |
| Pathology Associates International Corp. | Charles River Laboratories International Inc. (NYSE:CRL) | 12/21 | 1/9 | $37 | Charles River completed its acquisition of Pathology for $25M in cash and $12M as a convertible note |
| Permatec Holding AG (Switzerland) | Medi-Ject Corp. (MEDJ) | 1/30 | 1/30 | $14 | Medi-Ject issued 2.9M shares worth about $14M in exchange for all the outstanding stock of Permatec |
| Systems Integration Drug Discovery Co. Inc. | Discovery Partners International Inc. (DPII) | 12/21 | 1/01 | ND | Discovery Partners purchased Systems Integration |